Plain-English translation of NCT06129175 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a new treatment called , which contains stem cells derived from umbilical cord tissue. Researchers believe these cells may help repair damage caused by stroke and reduce disability by promoting the brain's natural healing processes. You would receive either the stem cell treatment or a placebo (a dummy infusion with no active cells), along with standard stroke care.
Stroke remains one of the leading causes of serious disability worldwide, and current treatments have limited success in helping people recover. Early research suggests that this medication may help the brain heal itself after a stroke by reducing inflammation, protecting nerve tissue, and promoting the growth of new blood vessels and neural connections.
You likely qualify if…
You likely don't qualify if…
You would be randomly assigned to receive either the stem cell infusion or a placebo injection into your bloodstream, plus standard stroke treatment. You would stay in the hospital and undergo brain imaging scans (MRI), blood tests, and regular assessments of your neurological function and ability to perform daily activities at specific time points over several weeks to months. The study team would track your recovery and any side effects throughout your participation.
AI-generated summary from trial data · Jun 13, 2026 · Not medical advice
Malaysia